Adlai Nortye Ltd American Depositary Shares (ANL)

$1.50 +0.03 (2.04%)
Market Cap 57.20M
Revenue (ttm) 0.00
Net Income (ttm) -51.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.03
Volume 846
Avg Vol 19,594
Day's Range N/A - N/A
Shares Out 36.90M
Stochastic %K 21%
Beta -0.83
Analysts Hold
Price Target $9.00

Company Profile

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is i...

Industry: Biotechnology
Sector: Healthcare
Phone: 848 230 7430
Address:
New Jersey Biotechnology Development Center, 2nd floor 685 US Hwy 1, North Brunswick Township, United States
FDAvalid
FDAvalid Apr. 27 at 10:55 PM
$ANL $ELTX $ERAS $RVMD $VSTM Bulls: “ERAS is breathing easy!” 😌📈 8K: Death from Grade 3 pneumonitis ➡️ Grade 5 🪦 Market: starts hyperventilating 😮‍💨📉 You can’t steroid your way out of this chart 📊�
1 · Reply
LiveCommander
LiveCommander Apr. 25 at 9:56 PM
People who comment on $RVMD RM-055 preclinical data as predicting replacement to Pan RAS molecule glues should try to understand how the drug works from detailed slides at RVMD website. Daraxonrasib causes some level of GTP hydrolysis and contributes to enhancing RAS off$ERAS and $ANL ) also kill cell lines with RAS amplification. Phase 1 to start in q 4. And people need to stop being ahead of themselves. Although Cool discovery but no details on how it enhances hydrolysis.
0 · Reply
Alt_Fuel
Alt_Fuel Apr. 24 at 8:29 AM
$VSTM Verastem partner in KRAS ON / OFF " GenFleet Therapeutics " - New 52 Week High on April 24, 2026 $ANL $ELTX $ERAS $RVMD Apr. 23, 2026-- Verastem Oncology $VSTM will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-report-first-quarter-2026-financial-results
1 · Reply
StockScanners
StockScanners Apr. 21 at 3:31 AM
$ANL reached 17.30
0 · Reply
Alt_Fuel
Alt_Fuel Apr. 20 at 5:42 PM
$VSTM $ANL $ELTX $ERAS $RVMD BTIG Reiterates Buy on Verastem, Maintains $19 Price Target 01:12 PM EDT, April 20, 2026 Updated 27 minutes ago, April 20, 2026 at 1:12 PM EDT 1:12 PM EDT, April 20, 2026 (Benzinga Newswire) BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.
1 · Reply
DARKP00L
DARKP00L Apr. 20 at 10:14 AM
$ANL 06:14 on Apr. 20 2026 HC Wainwright & Co. Maintains Buy on Adlai Nortye, Raises Price Target to $20 #tradeideas
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 19 at 3:56 PM
ras targeted small molecule landscape (not comprehensive). $RVMD $ERAS $VSTM $ANL
1 · Reply
StockScanners
StockScanners Apr. 18 at 3:19 AM
$ANL keep watch if this holds above 15.37
0 · Reply
Floridaorange
Floridaorange Apr. 17 at 1:45 PM
$IBRX can we have an $ANL squueze here or too much to ask?
1 · Reply
DARKP00L
DARKP00L Apr. 16 at 1:10 PM
$ANL 07:42 on Apr. 16 2026 Adlai Nortye shares are trading higher after the company announced it has entered into a $150 million securities purchase agreement for a private investment in public equity financing. #tradeideas
0 · Reply
Latest News on ANL
Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright

2026-04-20T10:21:49.000Z - 23 days ago

Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

Apr 16, 2026, 7:00 AM EDT - 27 days ago

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

Adlai Nortye Ltd (ADR) trading resumes

2026-04-15T14:15:36.000Z - 4 weeks ago

Adlai Nortye Ltd (ADR) trading resumes

Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

2026-04-15T13:36:44.000Z - 4 weeks ago

Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

Leerink bullish on Adlai Nortye, initiates with an Outperform

2026-03-20T10:37:59.000Z - 7 weeks ago

Leerink bullish on Adlai Nortye, initiates with an Outperform

Adlai Nortye initiated with an Outperform at Leerink

2026-03-20T10:16:32.000Z - 7 weeks ago

Adlai Nortye initiated with an Outperform at Leerink

Adlai Nortye files to sell $600M of Class A ordinary shares

2026-03-10T12:59:01.000Z - 2 months ago

Adlai Nortye files to sell $600M of Class A ordinary shares

Adlai Nortye files to sell 64.62M Class A ordinary shares for holders

2026-03-10T12:58:30.000Z - 2 months ago

Adlai Nortye files to sell 64.62M Class A ordinary shares for holders

Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic

2026-02-13T14:45:43.000Z - 3 months ago

Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic

Adlai Nortye upgraded to Buy from Neutral at H.C. Wainwright

2026-02-13T14:41:06.000Z - 3 months ago

Adlai Nortye upgraded to Buy from Neutral at H.C. Wainwright

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Feb 12, 2026, 4:00 AM EST - 3 months ago

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Adlai Nortye prices 64.6M shares at $2.17 in private placement

2026-02-03T12:10:38.000Z - 3 months ago

Adlai Nortye prices 64.6M shares at $2.17 in private placement

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Feb 3, 2026, 7:00 AM EST - 3 months ago

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Adlai Nortye Ltd (ADR) trading resumes

2026-01-30T14:45:22.000Z - 3 months ago

Adlai Nortye Ltd (ADR) trading resumes

Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

2026-01-30T14:40:32.000Z - 3 months ago

Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

Adlai Nortye initiated with a Buy at Lucid Capital

2026-01-29T11:11:30.000Z - 3 months ago

Adlai Nortye initiated with a Buy at Lucid Capital

Adlai Nortye enters exclusive license agreement with ASK Pharm for AN9025

2025-12-29T11:10:52.000Z - 4 months ago

Adlai Nortye enters exclusive license agreement with ASK Pharm for AN9025

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Dec 29, 2025, 6:00 AM EST - 4 months ago

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 11:07 PM EDT - 7 months ago

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Adlai Nortye downgraded to Neutral from Buy at H.C. Wainwright

2025-06-02T15:25:22.000Z - 1 year ago

Adlai Nortye downgraded to Neutral from Buy at H.C. Wainwright

Adlai Nortye downgraded at H.C. Wainwright after ‘unfortunate’ trial miss

2025-06-02T15:25:12.000Z - 1 year ago

Adlai Nortye downgraded at H.C. Wainwright after ‘unfortunate’ trial miss

Adlai Nortye initiated with a Buy at H.C. Wainwright

2024-09-04T10:05:28.000Z - 1 year ago

Adlai Nortye initiated with a Buy at H.C. Wainwright

Adlai Nortye expects cash to fund operations for at least next 12 months

2024-08-08T12:50:25.000Z - 1 year ago

Adlai Nortye expects cash to fund operations for at least next 12 months

Adlai Nortye announces pipeline updates

2024-08-08T12:49:45.000Z - 1 year ago

Adlai Nortye announces pipeline updates

Adlai Nortye appoints Roger Sawhney to board of directors

2024-08-08T12:48:05.000Z - 1 year ago

Adlai Nortye appoints Roger Sawhney to board of directors

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

May 23, 2024, 9:03 PM EDT - 2 years ago

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

May 22, 2024, 8:00 AM EDT - 2 years ago

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Mar 29, 2024, 6:00 AM EDT - 2 years ago

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Nov 17, 2023, 7:30 AM EST - 2 years ago

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Oct 23, 2023, 8:12 AM EDT - 2 years ago

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Oct 3, 2023, 12:05 PM EDT - 2 years ago

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Sep 29, 2023, 2:46 AM EDT - 2 years ago

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Cancer treatment company Adlai Nortye sets terms in IPO

Aug 11, 2023, 7:05 AM EDT - 2 years ago

Cancer treatment company Adlai Nortye sets terms in IPO

FDAvalid
FDAvalid Apr. 27 at 10:55 PM
$ANL $ELTX $ERAS $RVMD $VSTM Bulls: “ERAS is breathing easy!” 😌📈 8K: Death from Grade 3 pneumonitis ➡️ Grade 5 🪦 Market: starts hyperventilating 😮‍💨📉 You can’t steroid your way out of this chart 📊�
1 · Reply
LiveCommander
LiveCommander Apr. 25 at 9:56 PM
People who comment on $RVMD RM-055 preclinical data as predicting replacement to Pan RAS molecule glues should try to understand how the drug works from detailed slides at RVMD website. Daraxonrasib causes some level of GTP hydrolysis and contributes to enhancing RAS off$ERAS and $ANL ) also kill cell lines with RAS amplification. Phase 1 to start in q 4. And people need to stop being ahead of themselves. Although Cool discovery but no details on how it enhances hydrolysis.
0 · Reply
Alt_Fuel
Alt_Fuel Apr. 24 at 8:29 AM
$VSTM Verastem partner in KRAS ON / OFF " GenFleet Therapeutics " - New 52 Week High on April 24, 2026 $ANL $ELTX $ERAS $RVMD Apr. 23, 2026-- Verastem Oncology $VSTM will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-report-first-quarter-2026-financial-results
1 · Reply
StockScanners
StockScanners Apr. 21 at 3:31 AM
$ANL reached 17.30
0 · Reply
Alt_Fuel
Alt_Fuel Apr. 20 at 5:42 PM
$VSTM $ANL $ELTX $ERAS $RVMD BTIG Reiterates Buy on Verastem, Maintains $19 Price Target 01:12 PM EDT, April 20, 2026 Updated 27 minutes ago, April 20, 2026 at 1:12 PM EDT 1:12 PM EDT, April 20, 2026 (Benzinga Newswire) BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.
1 · Reply
DARKP00L
DARKP00L Apr. 20 at 10:14 AM
$ANL 06:14 on Apr. 20 2026 HC Wainwright & Co. Maintains Buy on Adlai Nortye, Raises Price Target to $20 #tradeideas
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 19 at 3:56 PM
ras targeted small molecule landscape (not comprehensive). $RVMD $ERAS $VSTM $ANL
1 · Reply
StockScanners
StockScanners Apr. 18 at 3:19 AM
$ANL keep watch if this holds above 15.37
0 · Reply
Floridaorange
Floridaorange Apr. 17 at 1:45 PM
$IBRX can we have an $ANL squueze here or too much to ask?
1 · Reply
DARKP00L
DARKP00L Apr. 16 at 1:10 PM
$ANL 07:42 on Apr. 16 2026 Adlai Nortye shares are trading higher after the company announced it has entered into a $150 million securities purchase agreement for a private investment in public equity financing. #tradeideas
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 16 at 12:16 PM
$ANL (+16.1% pre) Cancer drug developer Adlai Nortye lines up $150M from investors https://ooc.bz/l/98979
0 · Reply
DARKP00L
DARKP00L Apr. 16 at 11:43 AM
$ANL 07:42 on Apr. 16 2026 Adlai Nortye shares are trading higher after the company announced it has entered into a $150 million securities purchase agreement for a private investment in public equity financing. #tradeideas
0 · Reply
Paraboljoker
Paraboljoker Apr. 16 at 11:21 AM
$MGRT and $WSHP i gave the bottom here🤌🏼🎁 $ATXG sexy setup with news recent next👉 nanofloat🐉 $ANL ww
0 · Reply
DARKP00L
DARKP00L Apr. 16 at 11:05 AM
$ANL 07:02 on Apr. 16 2026 Adlai Nortye Enters Into Securities Purchase Agreement For Private Investment In Public Equity Financing That Is Expected To Result In Gross Proceeds Of ~$150M #tradeideas
0 · Reply
Paraboljoker
Paraboljoker Apr. 16 at 11:02 AM
$WSHP $ANL big hype china + lowfloaters $ATXG heating up👀
0 · Reply
EddieH2020
EddieH2020 Apr. 15 at 5:27 PM
$ANL What was the news? Always love when Seedy takes the L lmao
0 · Reply
bobaboiz
bobaboiz Apr. 15 at 3:17 PM
$ANL love a nice discount
0 · Reply
gigafactory
gigafactory Apr. 15 at 3:01 PM
$ANL is this why its dropping today? anyone care to say what's going on
1 · Reply
TKkamen
TKkamen Apr. 15 at 2:59 PM
$ANL What on earth is going on...
0 · Reply
Scarlett2228
Scarlett2228 Apr. 15 at 2:16 PM
$ANL wow!
0 · Reply
Alt_Fuel
Alt_Fuel Apr. 15 at 9:07 AM
$VSTM $ANL $ELTX $ERAS $RVMD American Association for Cancer Research (AACR) Annual Meeting - April 17–22, 2026 Presentations: $VSTM - Multiple presentations (April 20-22) covering preclinical work on RAF, MEK, and FAK inhibition in melanoma, and pre-clinical data on the KRAS G12D inhibitor VS-7375 (including Abstract #lb183/LB197, showing strong tumor reduction in pancreatic cancer models) The above are related to the VSTM and GenFleet Therapeutics ... Verastem has license outside of China GenFleet’s oral KRAS G12D inhibitor GFH375 secured a second Breakthrough Therapy Designation in China for metastatic pancreatic cancer. NOTE - Latest Official News - April 8, 2026 at 8:08 PM ... GenFleet’s KRAS G12D Drug Wins Second Breakthrough Tag as First Pancreatic Cancer Monotherapy in China ... BTD in PDAC by CDE for GFH375, following BTD in NSCLC in March 2026 !!!
0 · Reply